BioNTech (NASDAQ:BNTX) Shares Down 5.9%

BioNTech SE (NASDAQ:BNTXGet Rating)’s share price dropped 5.9% during mid-day trading on Friday . The company traded as low as $147.12 and last traded at $147.60. Approximately 18,627 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 977,038 shares. The stock had previously closed at $156.92.

Analysts Set New Price Targets

Several research firms recently commented on BNTX. Cowen began coverage on shares of BioNTech in a research report on Wednesday, August 17th. They set a “market perform” rating and a $177.00 price target on the stock. Cowen started coverage on shares of BioNTech in a report on Wednesday, August 17th. They set a “market perform” rating on the stock. Canaccord Genuity Group cut their price target on BioNTech from $200.00 to $191.00 and set a “buy” rating for the company in a research note on Tuesday, November 8th. The Goldman Sachs Group lowered their price objective on BioNTech from $200.00 to $177.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 8th. Finally, SVB Leerink upped their target price on BioNTech from $223.00 to $224.00 and gave the company an “outperform” rating in a research report on Friday, July 29th. Seven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $215.92.

BioNTech Price Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.06 and a current ratio of 5.37. The company has a market cap of $37.50 billion, a price-to-earnings ratio of 3.49 and a beta of 0.12. The business has a fifty day moving average price of $139.40 and a 200 day moving average price of $148.54.

BioNTech (NASDAQ:BNTXGet Rating) last issued its earnings results on Monday, November 7th. The company reported $6.98 EPS for the quarter, topping the consensus estimate of $3.42 by $3.56. BioNTech had a return on equity of 66.45% and a net margin of 55.72%. The firm had revenue of $3.46 billion during the quarter, compared to the consensus estimate of $1.90 billion. During the same quarter in the previous year, the firm earned $14.56 earnings per share. The business’s quarterly revenue was down 43.1% on a year-over-year basis. As a group, research analysts anticipate that BioNTech SE will post 34.03 earnings per share for the current year.

Institutional Trading of BioNTech

Hedge funds have recently added to or reduced their stakes in the stock. Baillie Gifford & Co. lifted its stake in shares of BioNTech by 7.7% in the 2nd quarter. Baillie Gifford & Co. now owns 7,262,980 shares of the company’s stock valued at $1,082,910,000 after acquiring an additional 518,283 shares during the last quarter. Primecap Management Co. CA boosted its stake in shares of BioNTech by 1.3% during the first quarter. Primecap Management Co. CA now owns 4,242,068 shares of the company’s stock valued at $723,527,000 after purchasing an additional 54,950 shares in the last quarter. Artisan Partners Limited Partnership grew its holdings in shares of BioNTech by 200.7% during the third quarter. Artisan Partners Limited Partnership now owns 2,228,913 shares of the company’s stock worth $300,636,000 after purchasing an additional 1,487,687 shares during the last quarter. Flossbach Von Storch AG bought a new stake in shares of BioNTech during the first quarter worth about $327,490,000. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of BioNTech by 21.0% in the second quarter. Price T Rowe Associates Inc. MD now owns 1,847,935 shares of the company’s stock valued at $275,527,000 after buying an additional 321,110 shares during the period. Institutional investors and hedge funds own 13.77% of the company’s stock.

About BioNTech

(Get Rating)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.

Recommended Stories

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.